Cadonilimab plus chemotherapy ± bevacizumab as 1L treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): a randomized, double-blind, placebo-controlled phase 3 study (Compassion-16)

被引：0
|
作者：
Wu, Xiaohua [1 ]
Sun, Yang [2 ]
Yang, Hongying [3 ]
Wang, Jing [4 ,5 ]
Lou, Hanmei [6 ]
Li, Dan [7 ]
Wang, Ke [8 ]
Zhang, Hui [9 ]
Wu, Tao [10 ]
Li, Yuzhi [11 ]
Wang, Chunyan [12 ]
Li, Guiling [13 ]
Wang, Yifeng [14 ]
Li, Dapeng [15 ]
Tang, Ying [16 ]
Pan, Mei [17 ]
Cai, Hongyi [18 ]
Liu, Ting [19 ]
Xia, Michelle [19 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fujian Med Univ, Clin Oncol Sch, Fujian Canc Hosp, Fuzhou, Peoples R China
[3] Yunnan Canc Hosp, Kunming, Peoples R China
[4] Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[5] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[6] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[7] Southwest Med Univ, Affiliated Hosp, Luzhou, Peoples R China
[8] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[9] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
[10] Changde First Peoples Hosp, Changde, Peoples R China
[11] Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China
[12] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[13] Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[14] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China
[15] Shandong First Med Univ, Canc Hosp, Jinan, Peoples R China
[16] Chongqing Univ, Affiliated Canc Hosp, Chongqing, Peoples R China
[17] Jiangxi Maternal & Child Hlth Hosp, Nanchang, Peoples R China
[18] Gansu Prov Hosp, Lanzhou, Peoples R China
[19] Akeso Biopharm Inc, Zhongshan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB014/#167
引用
收藏
页码：A1 / A2
页数：2
相关论文
共 50 条
  • [1] Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
    Wu, Xiaohua
    Sun, Yang
    Yang, Hongying
    Wang, Jing
    Lou, Hanmei
    Li, Dan
    Wang, Ke
    Zhang, Hui
    Wu, Tao
    Li, Yuzhi
    Wang, Chunyan
    Li, Guiling
    Wang, Yifeng
    Li, Dapeng
    Tang, Ying
    Pan, Mei
    Cai, Hongyi
    Wang, Weihu
    Yang, Bing
    Qian, Hua
    Tian, Qiuhong
    Yao, Desheng
    Cheng, Ying
    Wei, Bing
    Li, Xiumin
    Wang, Tao
    Hao, Min
    Wang, Xiaohong
    Wang, Tiejun
    Ran, Juntao
    Zhu, Hong
    Zhu, Lijing
    Liu, Xianling
    Li, Yunxia
    Chen, Lihong
    Li, Qingshan
    Yan, Xiaojian
    Wang, Fei
    Cai, Hongbing
    Zhang, Yunyan
    Liang, Zhiqing
    Liu, Funan
    Huang, Yi
    Xia, Bairong
    Qu, Pengpeng
    Zhu, Genhai
    Chen, Youguo
    Song, Kun
    Sun, Meili
    Chen, Zhengzheng
    LANCET, 2024, 404 (10463): : 1668 - 1676
  • [2] KEYNOTE-826: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Tewari, K.
    Caceres, M. V.
    Alexandre, J.
    Monk, B.
    Fehm, T.
    Colombo, N.
    Hasegawa, K.
    Dubot, C.
    Li, J. J.
    Stein, K.
    Keefe, S.
    Shapira-Frommer, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A162 - A162
  • [3] KEYNOTE-826: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
    Shapira-Frommer, Ronnie
    Alexandre, Jerome
    Monk, Bradley
    Fehm, Tanja N.
    Colombo, Nicoletta
    Caceres, Maria V.
    Hasegawa, Kosei
    Dubot, Coraline
    Li, Jerry Jing
    Stein, Karen
    Keefe, Stephen Michael
    Tewari, Krishnansu Sujata
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase III KEYNOTE-826 study
    Colombo, N.
    Dubot, C.
    Lorusso, D.
    Caceres, V.
    Hasegawa, K.
    Shapira-Frommer, R.
    Tewari, K. S.
    Salman, P.
    Hoyos, E.
    Yanez, E.
    Gumus, M.
    De Mendoza, M. Olivera Hurtado
    Samouelian, V.
    Castonguay, V.
    Arkhipov, A.
    Toker, S.
    Li, K.
    Keefe, S. M.
    Monk, B. J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1307 - S1308
  • [5] A randomized, double-blind, placebo-controlled phase III study to evaluate AK104 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer
    Wu, Xiaohua
    Wang, Jing
    Huang, Yi
    Li, Yuzhi
    Sun, Yang
    Wang, Ke
    Xia, Michelle
    Li, Baiyong
    Liu, Wei
    CANCER RESEARCH, 2022, 82 (12)
  • [6] Cost-effectiveness analysis of a first-line treatment with cadonilimab plus platinum-based chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer in China: COMPASSION-16 trial
    Ding, Yiling
    Wang, Chunping
    Shu, Yamin
    Wang, Jinglin
    Zhang, Qilin
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2025, 18 (01)
  • [7] BACCI: A phase II randomized, double-blind, placebo-controlled study of capecitabine bevacizumab plus atezolizumab versus capecitabine bevacizumab plus placebo in patients with refractory metastatic colorectal cancer.
    Mettu, Niharika B.
    Niedzwiecki, Donna
    Boland, Patrick Mckay
    Fakih, Marwan
    Arrowood, Christy
    Bolch, Emily
    Hurwitz, Herbert
    Grothey, Axel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo- controlled, phase 3 trial
    Monk, Bradley J.
    Tewari, Krishnansu S.
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Guemues, Mahmut
    Mendoza, Mivael Olivera Hurtado de
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Nguyen, Allison Martin
    Monberg, Matthew J.
    Colombo, Nicoletta
    Lorusso, Domenica
    LANCET ONCOLOGY, 2023, 24 (04): : 392 - 402
  • [9] KEYNOTE-826: FINAL OVERALL SURVIVAL RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF PEMBROLIZUMAB plus CHEMOTHERAPY VS PLACEBO plus CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Monk, Bradley J.
    Colombo, Nicoletta
    Tewari, Krishnansu Sujata
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    De Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Keefe, Stephen Michael
    Lorusso, Domenica
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A420 - A420
  • [10] KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
    Monk, Bradley J.
    Colombo, Nicoletta
    Tewari, Krishnansu Sujata
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    de Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Keefe, Stephen Michael
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345